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Fred A. Weaver, MD, MMM, Los Angeles, CalifLet me begin by thanking all of you for the honor of
being this year’s President of the Society for Clinical
Vascular Surgery (SCVS), a Society founded and dedicated
to the educational enrichment of practicing vascular sur-
geons and specialists. For 42 years, this Society has pro-
vided real-world, practical vascular education to those
entrusted with the privilege of caring for patients with
vascular disease. It has been my honor to serve this
wonderful Society.
As is frequently the custom in a Presidential Address, I
would like to begin by thanking a few special individuals,
individuals who have been of great support to me both pro-
fessionally and personally. First, my vascular surgery men-
tors at Vanderbilt, Dr William Edwards, Dr Richard
Dean, Dr Joe Mulherrin, and the late Dr W. Andrew
Dale, who encouraged me to pursue a career in vascular
surgery and then gave me the privilege of being their
vascular surgery fellow. Their technical proﬁciency and
teaching prowess in the operating room was a special gift
that I have used to the best of my ability over the years.
In addition, they had a visionary understanding that
catheter-based techniques were the future of vascular sur-
gery. At a time in the 1980s when most vascular surgeons
relied on radiologists for angiography and catheter-based
interventions, Drs Edwards, Mulherrin, and Dale per-
formed some of their own angiography and were early
adopters of catheter-based interventions. Dr Edwards often
told me that I would have nothing to do if I did not ride
the endovascular wave on the horizon. How right he was!the Division of Vascular Surgery and Endovascular Therapy, Keck
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6In Southern California, where I have been for the last
28 years, Dr Albert Yellin, who is not with us today but
a name familiar to many of you, was my senior partner in
vascular surgery at the University of Southern California
(USC). Together, we wrote many articles concerning the
management of vascular trauma and atherosclerotic
vascular disease. In 1991, as Chief of the Division of
Vascular Surgery with yours truly as a junior faculty mem-
ber, he laid the foundation for the vascular surgery services
at the then-new USC University Hospital. That hospital,
now the Keck Hospital of USC, currently has a faculty of
seven vascular surgeons, integrated and 5þ2 residencies
in vascular surgery, and a robust research program based
on Dr Yellin’s initial foundation. It was my good fortune
to follow him as Division Chief. His wisdom and insight
have been invaluable to me over the years.
Dr Max Gaspar, a Founder and former President of this
Society, was a valued friend and mentor. As many of you
may know, Max passed away in October 2012. Max was
one of the founding fathers of vascular surgery, particularly
on the West Coast. He was a technically superb surgeon
whose knowledge and insight into the management of pa-
tients with vascular disease was impressive. When I arrived
as a new faculty member at USC, Max presided over a
weekly vascular surgery conference attended by 10 to 20
vascular surgeons who practiced in the city of Los Angeles.
Many of those surgeons have names you would recognize,
such was the respect for Max’s abilities as a vascular sur-
geon and teacher.
Finally, none of us succeeds without the selﬂess support
of others. Great partners and staff have blessed my profes-
sional career, and what they do day in and day out for pa-
tients is special. In particular, I would like to recognize Dr
Steven Katz and Dr Vincent Rowe, who have been my
partners for the last 15 years. It has been my good fortune
to have their wise counsel, insight, and surgical talent as
part of my professional career. Their abilities as surgeons
and qualities as human beings have graced our partnership
beyond measure. Thank you, Steve and Vince. And to all
the others, and there are many who I have not mentioned,
you have my greatest appreciation and thanks for what you
have given to me both personally and professionally.
For all of us, there is that one person, that rock, who
steadies us in times of confusion and cheers us in times
of success. For me, Becky, my wife of 34 years, has been
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matedthe love of my life. She is the mother of our three
boys who have made me so very proud. She was there
for them when I was in the operating room, taking care
of a sick patient, or travelingdalways there and always on
call; I am a very lucky guy.
Last year, Dr Sam Money in his Presidential Address to
this Society asked, Are we unique?1 The answer was in the
afﬁrmative, and I think we are all proud of the road traveled
by vascular surgery to this pivotal time in our existence. No
longer are we at odds with the house of surgery about our
unique role in the care of the surgical patient. No longer
are we required to justify why we need to have access to
ﬂuoroscopic suites; in fact, many hospitals are falling over
themselves to build hybrid suites for us to perform both
open and endovascular procedures. In short, we have the
good fortune of practicing at a time when vascular surgery
is experiencing a unique maturation and identity as a spe-
cialty, much as many specialties before us, such as orthope-
dics, neurosurgery, cardiac surgery, and urology, among
others. At such a time, there is value in reminding ourselves
of the journey traveled and what that portends for the
future. To encapsulate all that has gone before in the gen-
esis of our specialty would be an undertaking beyond your
patience. So this history lesson is through the lens of tech-
nology and innovation and the innovators that made it
happen.
I have entitled this address “Disruptive Technology
and the Making of Contemporary Vascular Surgery.” It is
hoped that it will serve as a gentle reminder that as Sir Isaac
Newton stated, “If I have seen a little further it is by stand-
ing on the shoulders of giants.”
In the December 31, 1999, issue of Time magazine,
Albert Einstein was named the Person of the Century.
Many would suggest that he was the “Person” of the last
500 years, given his contributions to our understanding
of space and time. But that is not our concern today. For
today he is of interest because he had an abdominal aortic
aneurysm and died of rupture of that aneurysm. To wit, he
provides a very striking context for just how far vascular
surgery has come since the middle of the 20th century.
His aneurysm was diagnosed in the 1940s, at a time
when graft replacement was unknown; prosthetic arterial
substitutes had yet to be developed. His aneurysm was
managed by cellophane wrapping by Dr Rudolf Nissen,
the surgeon who gave us the Nissen fundoplication. As
was soon learned, aneurysm wrapping did not work, and
his aneurysm ruptured in 1955. Due to the efforts of Dr
Arthur Voorhees, Dr Sterling Edwards, and Dr Michael
DeBakey, prosthetic graft replacement for aortic aneurysms
had become a reality by the mid-1950s. Einstein was
offered repair, which he refused: “I want to go when I
want. It is tasteless to prolong life artiﬁcially. I have done
my share, it is time to go. I will do it elegantly.” He died
3 days later of aneurysm rupture.
Many forefathers of vascular surgery were involved in
the disruptive technology of graft development, but
Michael DeBakey and his wife’s sewing machine were thegenesis of the Dacron graft. It is a fascinating story, which
could not be relived today in our hyper-regulatory environ-
ment. As retold by Dr DeBakey in a Journal of Vascular
Surgery interview in 1996, he was interested in purchasing
nylon cloth material to make a vascular graft as had been
suggested by Voorhees.2 He went to the department store;
they were out of nylon but did have this new cloth material,
Dacron. He bought some sheets of Dacron and using his
wife’s sewing machine created Dacron tubes. A couple of
years of laboratory work that involved replacing the aorta
of dogs with the new Dacron graft convinced him it was
time to move the concept of Dacron graft replacement to
patients. So he did, and the rest is history.
Not enough can be said about Dr DeBakey and his
contributions to vascular surgery. He and Dr Stanley Craw-
ford pioneered much of aortic surgery, demonstrating that
large sections of the aorta including those with visceral/
renal branches could be replaced.
There are many other important surgeons in this story,
and not all of them can be mentioned, but it was Dr Emer-
ick Szilagyi in a presentation to the American Surgical As-
sociation who documented that aortic replacement for
abdominal aortic aneurysms was safe and more effective
than nonoperative management,3 an assertion we all accept
today as a given, although the threshold for repair con-
tinues to be a subject of debate in the era of endovascular
aneurysm repair (EVAR).
Until EVAR, open replacement of the aorta by a
Dacron graft was the procedure of choice for treatment
of an abdominal aortic aneurysm. Few thought this would
ever change, and it would not have without the advent of
endovascular therapy. In the 1950s, the concept of
approaching vascular disease through the artery as opposed
to outside the artery was yet to be born. Certainly, it was
not on the mind of surgeons who performed aortic proce-
dures. Vascular disease was approached from outside in,
with either replacement of the diseased vessel or removal
of the disease by endarterectomy, a technique developed
by Dos Santos and popularized for carotid procedures
and procedures on other vascular beds by Drs DeBakey,
Norman Freeman, Edwin J. Wylie, Max Gaspar, Wiley
Barker, and others. After all, we the surgeons used the
technology, if you will, of our hands, eyes, motor skills,
and surgical judgment in the operating room to ﬁx the
problem.
Enter Dr Charles Dotter, a University of Oregon radi-
ologist who described and performed the ﬁrst endovascular
intervention. His speciﬁc intent was to treat vascular disease
from inside the blood vessel to eliminate the large incision
required for arterial exposure and thus minimize patient
discomfort and accelerate recovery. As he stated in a
1963 address at the Czechoslovakia Radiologic Congress,
“The angiographic catheter can be more than a tool for
passive means for diagnostic observation; used with imagi-
nation it can become an important surgical instrument.”4
He was clearly way ahead of his time.
Many of his peers and all surgeons referred to him as
“Crazy Charlie” for describing what has become a basic
Fig. Distribution of peripheral vascular interventions (Current
Procedural Terminology code 37205) by specialty based on
Medicare physician claims, 2000 and 2010.7
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transluminal angioplasty in a 1964 publication in Circula-
tion, a paper that should be in every vascular surgeon’s li-
brary.5 His paper described “transluminal angioplasty” of
arterial stenoses and occlusions using graduated Teﬂon di-
lators that were passed endoluminally under ﬂuoroscopic
guidance. The concept of “Dottering” the lesion was
born. Of interest, Bill Cook, the founder of Cook Medical,
worked very closely with Dr Dotter on many of his endo-
luminal devices and therapies, permitting expanded appli-
cation of the technique and establishing Cook in the
endovascular arena. Consequently, with the later develop-
ment of balloon angioplasty by Dr Andreas Gruentzig
and the metal endoluminal stent by Dr Julio Palmaz, effec-
tive catheter-based therapies were established.
The reticence of surgeons to adopt catheter-based
therapies was signiﬁcant. The attitude of surgeons to
Dotter’s idea is well demonstrated by a brief anecdote.
Dr Dotter once received an order for a lower extremity
angiogram by a surgeon with the explicit warning,
“Visualize but do not try to ﬁx.”6 Dotter dutifully did
not treat the lesion of interest to the surgeon, an occluded
superﬁcial femoral artery, but did selectively treat a stenosis
of the profunda femoris artery. The subsequent superﬁcial
femoral artery surgical revascularization failed, but Dotter’s
treatment remained patent for many years, preserving
the patient’s limb. He was not immune to sharing this
anecdote far and wide, particularly in front of his critics.
I believe it is a point of distinction for the SCVS that
many of our past leaders were instrumental in leading
vascular surgery into the endovascular era. I will mention
two, Dr Kim Hodgson and Dr Alan Lumsden, both Past
Presidents of the SCVS who used this symposium to pro-
mote and teach endovascular techniques to vascular sur-
geons. Through Top Gun, hands-on simulation and
industry involvement dissemination of endovascular skills
was accelerated in the vascular surgery community. In so
many ways, SCVS led the integration of endovascular inter-
ventions into the practice of vascular surgery. Where would
we be today without their efforts and the efforts of many
others who were early adopters and promoters? I think
nowhere!
As is shown by this graphic (Fig), in the year 2000, our
colleagues in cardiology and radiology, who realized much
earlier the value of endovascular therapy, were poised to be
the primary deliverers of catheter-based care.7 We were
destined to live the legacy of our colleagues in cardiac sur-
gery. But by 2010, vascular surgeons had reversed this
trend, thanks in large part to leaders in this Society.
Nevertheless, it is quite possible vascular surgery would
have missed the endovascular train leaving the station if it
was not for Dr Juan Parodi. Dr Parodi brilliantly synthe-
sized the technology of vascular grafts with the innovation
of endovascular therapy to transform the treatment of
aortic disease. He presented his initial experience at a na-
tional vascular meeting in the early 1990s. It was a standing
room only crowd, and I was fortunate as a young vascular
surgeon to have been there. But as is the case with mostinnovations, resistance was signiﬁcant. A case in point
was his seminal article, which described his unique innova-
tion. The manuscript was initially rejected for publication
by a major vascular journal with an editorial comment to
Dr Parodi that it was a crazy idea (where have we heard
that before?).8 Ultimately, the article was published in
another journal, the Annals of Vascular Surgery.9
Fast forward to today, reﬂect for a moment on the
consequence of his innovation. Our program is testimony
to how much has changed not just for aortic aneurysms
but for aortic dissections, transections, and other aortic pa-
thology. It has resulted in all the beneﬁts ﬁrst advanced by
Dotter but not imagined by Dotter for patients with aortic
disease. Furthermore, it was Parodi’s innovation more than
any other that made it impossible for the house of surgery
to ignore the ever-expanding gulf between general surgery
and vascular surgery.
But application of Parodi’s innovation and subsequent
permutations requires imaging, for performing and inter-
preting imaging of the vascular system is a core competency
and requirement of every vascular surgeon in practice
today. Aortic procedures as described before are not
possible without the sophisticated computed tomography
and magnetic resonance imaging available in current prac-
tice. These technologies developed in the 1980s have
permitted the successful application and expansion of Par-
odi’s idea. Without body imaging technology, successful
endovascular therapy of the aorta is less feasible or may
be not feasible at all.
However, there is another imaging construct that
needs to be mentioned because its contributions are no
less important and in many ways more important. The
development of noninvasive imaging technology was
fundamental to deﬁning our specialty. For us today, this
technology is taken for granted, but it was not so in the
1970s. Dr Eugene Strandness is familiar to most of you,
but his impact on the practice of vascular surgery and the
understanding and management of vascular disease in gen-
eral is sometimes lost in the high-tech era in which we live.
The putative “Father of Noninvasive Vascular Diagnostics”
was a Professor of Surgery at the University of Washington
when he and a team of engineers published in 1974 the
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Doppler ﬂow detection.10
Inherent in this innovation was the concept of vascular
imaging combined with the objective physiologic measure-
ment of blood ﬂow. As was true with his predecessors in
innovation, his concept of objectively imaging and
measuring vascular physiology was dismissed by many.
Palpation of pulses, auscultation with a stethoscope, and
static angiographic images were thought to be all that
was required to treat a vascular patient.
However, the power of this technology could not be
ignored for it provided quantitative assessment of vascular
pathology and physiology inexpensively and noninvasively.
Through this technology, we have been able to monitor
and correct vascular disease before the clinical event. It
has revolutionized our approach as surgeons to the longitu-
dinal follow-up of our patients, which is a unique element
of our specialty. Furthermore, the natural history of
vascular disease, much of it described by Dr Strandness
and his many disciples in vascular surgery, is understood
more clearly, as is the durability and modes of failure of
many vascular reconstructions. I ﬁnd also that its use in
the operating room for completion imaging is one of the
best educational tools for teaching technical proﬁciency
to the vascular surgery trainee. The operator is provided
immediate real-time feedback concerning the technical ad-
equacy of the vascular reconstruction. This, over time, I
believe subtly and progressively allows reﬁnement of tech-
nique, leading closer and closer to technical perfection.
What I have described in the foregoing are innovators
and innovations that by deﬁnition are disruptive. A disrup-
tive technology or innovation as described by Clayton
Christensen in his book The Innovator’s Prescription is
one that may initially underperform compared with the
established technology but has features that customers
(ie, patients) value.11 Disruptive technologies are typically
cheaper, simpler, smaller, and frequently more convenient
to use. Furthermore, the maturation of a disruptive tech-
nology results in wider application of the technology
because the ease of use encourages new and novel
applications.
Disruptive technologies can lead to a process of crea-
tive destruction, a phrase coined by Joseph Schumpeter,
a famous Austrian-American economist.12 Although the
term as initially coined described economic events in a capi-
talist system, it has, I believe, general implications for any
social construct. In Schumpeter’s classic book Capitalism,
Socialism and Democracy, he described creative destruction
as a process “in which . the competition from the new
commodity, the new technology, the new source of supply,
the new type of organization . competition which com-
mands a decisive cost or quality advantage and which
strikes not at the margins of proﬁts and outputs of the
existing ﬁrms but at their foundations and very lives.” In
essence, innovators and innovation are relentlessly destroy-
ing the established order by disruptive forces, which both
destroy the established order and create an entirely new
order.Has that not been the case for vascular surgery during
the past 60 years? It is a specialty that in many ways has
been birthed by disruptive technology and the forces of
creative destruction. Today, it is accepted and recognized
that vascular surgery is a unique, independent specialty
with certain characteristics and heritage. For the more se-
nior ones of us here, we have experienced this remarkable
destruction and transformation ﬁrst hand.
Vascular surgery germinated from the context of gen-
eral surgery much like many other specialties, such as
neurosurgery and urology. The concept of graft replace-
ment and endarterectomy incubated in the 1950s began
to deﬁne a new specialty in the 1960s.
By 1961, two vascular surgery fellowships had been
established, both on the West Coast, the ﬁrst with Dr
Max Gaspar in Long Beach, the other with Dr Edwin J.
Wylie at the University of California at San Francisco.
The 1960s were a time of vascular surgery searching for
an identity, and it was Dr Wylie in his Presidential Address
in 1970 to the Eighteenth Meeting of the International
Cardiovascular Society who described the deﬁning charac-
teristics of vascular surgery.13
His address, “Vascular Surgery: A Quest for Excel-
lence,” made the simple but erudite argument that vascular
surgery was of a different nature than general surgery.
Vascular surgery, unlike general surgery, had few retriev-
able errors, that is, surgical errors that if made could be suc-
cessfully corrected.14 As an analogy, he compared the
potential of a reoperation for a leaking intestinal anasto-
mosis to retrieve the error of poor anastomotic technique
with the inability of reoperation to retrieve the error of a
poor arterial anastomosis that resulted in a stroke or
gangrenous limb. In his address, he planted the ﬂag for
vascular surgery as a unique specialty that required addi-
tional training beyond the traditional 5 years of general sur-
gery. His recommended training paradigm: 5 years of
general surgery with an additional 1 year of vascular sur-
gery. He suggested that criteria for vascular surgery
training should be developed by the Society for Vascular
Surgery and the International Cardiovascular Society. He
argued that the American Board of Surgery should not
certify one as a vascular surgeon without an additional
year of focused vascular surgery training.
What followed in the 1970s was a laborious process
that speciﬁcally deﬁned the scope of vascular surgery, the
type of training required, the duration of training, and
the organization and faculty required for training. Individ-
uals familiar to many of you, DeWeese, Szilagyi, Thomp-
son, Blaisdell, Wylie, and many others, participated in this
effort. But there was resistance from many quarters, most
notably the American Board of Thoracic Surgery and a
few on the American Board of Surgery who were con-
cerned with the continued “fragmentation” of general
surgery.15
Parenthetically, it was during this period that our Soci-
ety was formed by West Coast surgeons Peter Samuels,
Seymour Greenstone, Wiley Barker, Max Gaspar, Robert
Ozeran, Herbert Roedling, Andrew Scharff, and Roscoe
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regional than national meeting. The SCVS has now bloss-
omed from those regional beginnings into this wonderful
national society, dedicated to an annual educational
vascular experience, which serves not just practicing
vascular surgeons but those who are considering vascular
surgery as a career, those who are in training for vascular
surgery, and those who just recently began practicing
vascular surgery. The SCVS today provides a unique and
speciﬁc educational experience for vascular surgeons, just
as the founders envisioned.
Although efforts in the 1970s certainly provided much
needed deﬁnition to vascular surgery training, certiﬁcation
by the American Board of Surgery in Vascular Surgery did
not occur until 1982. Acceptance of Dr Wylie’s challenge
was slow in coming because of competing interests and
philosophic disagreements on the importance of additional
vascular surgery training for the general or thoracic surgeon
who chose to also practice vascular surgery. This was a time
of great frustration for many vascular surgeons. The frustra-
tion was expressed in articles, panels, and commentaries on
the importance of recognizing vascular surgery as a unique
deﬁnable specialty, distinct from general surgery. Disrup-
tive technology, in many ways, was the tipping point for
the next events.
It is 1996 at the American College of Surgeons
meeting in San Francisco; the leadership of the Society
for Vascular Surgery and the International Society for Car-
diovascular Surgery announce the incorporation of the
American Board of Vascular Surgery. Some in this room
were part of that effort. In essence, it was the collected
expression of the vascular surgery community that it was
time for the American Board of Surgery to, as Moses said
to Pharoah, “let my people [vascular surgeons] go.”16 As
you know, the American Board of Vascular Surgery did
not survive, but I believe that it was critical to the recogni-
tion of vascular surgery as a specialty. Formation of the
American Board of Vascular Surgery focused all of sur-
gery’s attention on the concepts ﬁrst articulated by Wylie.
Ultimately, a vascular surgery board within the American
Board of Surgery was formed, and with the Vascular Sur-
gery Board of the American Board of Surgery, focused,
vascular surgery training after graduation from medical
school is now a reality.
Dr Frank Veith, in his 1996 Presidential Address to the
Society for Vascular Surgery entitled “Darwin and Vascular
Surgery,” clearly summarized the issue facing vascular sur-
gery at the time.17 In brief, extinction, destruction if you
will, awaited vascular surgery if it did not adapt and
embrace catheter-based technology and aggressively pur-
sue the goal of being a unique independent specialty. Tech-
nology had disrupted the landscape, and if ignored,
extinction was imminent. The vascular surgery community
and the surgical community at large thankfully heeded his
advice.
It is 2014; our specialty is healthy and growing. We
have established our independence. Vascular surgery
training after medical school is a reality. New technologyto treat myriad vascular diseases is advancing at a rapid
pace. Now that our training programs are in place and
our primary position as providers of vascular care is
acknowledged, what are the next steps as informed by
our past? I offer three in closing.
Now that vascular surgery has arrived, we need to
inform the public and the medical community at large on
what our specialty offers. It is of great satisfaction to me
that those students applying for our integrated vascular res-
idency are very capable of deﬁning the vascular surgeon:
vascular surgeons treat vascular disease in any body cavity
or extremity and are not limited by anatomic boundaries;
vascular surgeons treat patients holistically and longitudi-
nally, thus we develop long-term relationships with our pa-
tients as opposed to many surgical and nonsurgical
specialties; vascular surgeons tailor the treatment to the in-
dividual patient because we possess a large and varied skill
set. We are able to do it all from nonoperative manage-
ment, to catheter-based intervention, to open repair. All
these aspects of vascular surgery were incubated and
birthed by the innovators and innovations described previ-
ously. This message needs to get out to the public, to hos-
pital administration, and to our medical community. It is a
large task, and our sister society, the Society for Vascular
Surgery, is also interested in this issue. The time is ripe
for us to consider combining our collective inﬂuence and
resources in an effort to highlight who we are and what
we do.
Second, as evidenced by this talk, technology is game
changing, but we all know evaluating the risks and beneﬁts
of alternative therapies is complex. Comparative effective-
ness research has been proposed as part of the answer to
this dilemma, and more than one billion dollars is con-
tained in the Affordable Care Act to pursue this initiative.
It will be interesting to see how this evolves, since much
of what we do at meetings such as this is present research
that in essence directly compares outcomes of one
approach to another or as compared to historical out-
comes. Dr Szilagyi’s paper to the American Surgical Asso-
ciation that was previously alluded to is an example. He
compared the effectiveness of graft replacement for aortic
aneurysms to observation alone. Conclusion, graft replace-
ment was more effective.
The entire specialty of vascular surgery came into being
to a greater or lesser degree by similar research, which at
the time was not termed comparative effectiveness.
Whether appropriate application of technology will be
enhanced, unchanged, or deterred by what is now being
proposed as comparative effectiveness research is an un-
known. Nevertheless, because our specialty is so technolog-
ically driven, we must pay attention to where comparative
effectiveness could take us. In that context, tracking your
patients and knowing your outcomes by being part of the
only national database dedicated to vascular disease, the
Vascular Quality Initiative (VQI), is, I believe, imperative.
It is a platform with the potential to compare and to
contrast vascular technology at a reasonable cost and in
the shortest amount of time, particularly if we are all
Table. Comparison of arterial reconstructions performed by general surgeons vs vascular surgeons, 2007 to 2009
Procedure
General surgeons (n ¼ 3362) Vascular surgeons (n ¼ 363)
Mean 6 SD Mediana (25th/75th percentile) Mean 6 SD Mediana (25th/75th percentile)
Aortic aneurysm repair 0.3 6 1.4 0 (0/0) 6.6 6 8.9 4 (1/8)
Cerebrovascular 1.9 6 7.7 0 (0/0) 24.2 6 23.9 20 (9/32)
Aortic occlusive 0.5 6 2.5 0 (0/0) 4.7 6 11.1 6 (2/12)
Infrainguinal obstructive 1.3 6 6.1 0 (0/0) 25 6 24.9 16 (7/27)
Total major vascular operations 10.0 6 50.6 0 (0/0) 191.5 6 208.8 132 (62/255)
SD, Standard deviation.
American Board of Surgery case log recertiﬁcation data.19
aInterquartile range is in parentheses.
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tion’s recent decision to use the VQI as the database for
post-approval study of thoracic EVAR for type B aortic dis-
sections. This places the VQI in a central position in
analyzing effectiveness in a real-world application. If suc-
cessful, look for expansion of this approach for comparison
of competing technologies.
Finally, our skills as open surgeons should not be
forgotten. In the end, this is what separates us from others
who treat vascular disease. A recent issue of the Vascular
Specialist expresses the concern of many that the skills to
perform open aortic surgery will disappear with the passing
of the present generation of senior vascular surgeons.
Currently, vascular surgery residents ﬁnish with a median
of only 25 open aortic procedures of any type, which means
half of the vascular surgery residents ﬁnish their training
with 25 or fewer aortic cases.18 This exposure to open
aortic surgery is clearly not adequate and not in the best in-
terests of our specialty or the patients we treat. Open aortic
surgery and other open reconstructive procedures are not
going away in my view anytime soon, but no doubt fewer
of them will be performed. A strategy needs to be formu-
lated to address this issue, and although simulation, skills
courses, and cadaver dissection can help, there is no substi-
tute for the real thing. Our resident applicants realize this
and in a recent survey listed the opportunity for open aortic
surgery as the most important item they were looking for in
a vascular surgery residency.
Efforts need to be initiated on how we can best
leverage the open vascular surgery that is still being per-
formed. Clearly, it would seem that general surgery
training does not need to include arterial reconstructive
procedures. As is shown in this graphic on vascular surgery
care in the United States 2007-2009 collated from Amer-
ican Board of Surgery recertiﬁcation data, general surgeons
are simply not performing these procedures, and the
younger general surgeons perform signiﬁcantly less than
the older generation general surgeons (Table).19 Conse-
quently, it follows that reconstructive arterial cases need
to be reserved whenever possible for the vascular surgery
trainee. We need to encourage this approach both at the
American Board of Surgery and Residency Review Com-
mittee for Surgery. Some resistance to this approach maystill exist, but common sense dictates that in the not too
distant future, open reconstructive vascular surgery will
be the exclusive purview of current vascular surgeons and
those now in training. We need to preserve this component
of our identity just as much as we needed to embrace
catheter-based interventions in the 1990s.
We need to get busy on this item in particular, other-
wise who will be there if someone such as Albert Einstein
requires a complicated aneurysm repair not amenable to
endovascular techniques? The only answer is for the
vascular surgeon to be there, just as we have always been
for the past 60 years. Thank you for your attention and
the privilege of serving as your President.REFERENCES
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